Establishing cause of action for antitrust conduct, for indirect purchaser recovery under State antitrust laws and for premerger notice of health care mergers and transactions; and imposing penalties.
SB785 would create a new Pennsylvania antitrust chapter titled the “Pennsylvania Open Markets” chapter in Title 12. The bill declares a purpose of promoting free enterprise and competition by prohibiting restraints of trade, monopolization, monopsonization, and acquisitions that may substantially lessen competition or create a monopoly or monopsony. It gives the Attorney General broad authority to investigate suspected violations, seek injunctions, divestiture, damages, restitution, disgorgement, and civil penalties, and to coordinate enforcement with federal and state authorities.
The bill also expands private enforcement. It grants standing to persons harmed by prohibited conduct, authorizes indirect purchaser recovery, allows class actions, and permits plaintiffs to recover treble damages or the full amount of overcharges or underpayments without requiring proof of individual reliance. Damages may be proven through aggregate or statistical methods, and prevailing plaintiffs may recover attorney fees, expert fees, and investigative costs. The bill further creates criminal penalties for knowing violations of the core antitrust prohibitions, classifying them as third-degree felonies with fines up to $1 million and imprisonment up to four years.
A major health care component requires advance notice to the Attorney General of certain health care mergers, acquisitions, and contracting affiliations. Parties to qualifying transactions involving health care facilities, health care facility systems, or provider organizations must provide notice at least 120 days before the effective date, and entities already filing under the federal Hart-Scott-Rodino Act must also provide those filings to the Attorney General. The bill applies this notice regime to some out-of-state transactions affecting Pennsylvania patients, imposes a civil penalty for noncompliance, and states that failure to comply does not itself create a private cause of action.
The bill would significantly affect state antitrust enforcement and health care transaction oversight by giving the Attorney General new investigative tools, broader remedies, and mandatory notice of material health care deals. It also requires Commonwealth agencies to assist enforcement and to notify the Department of Health and Insurance Department when relevant actions are brought or resolved. The chapter would be construed in harmony with federal antitrust law where practicable, but it expressly preserves state authority and says actions cannot be barred merely because the conduct affects interstate commerce.
No votes or committee transcripts were provided, so there is no recorded legislative sentiment or debate history in the supplied materials. Based on the bill text alone, the measure appears designed to strengthen antitrust enforcement and increase scrutiny of health care consolidation, but the absence of discussion or voting data means there is no documented support or opposition to summarize from the record provided.
SB785 would add a new antitrust and health care premerger-notification chapter to Title 12 of the Pennsylvania Consolidated Statutes, creating new substantive prohibitions, enforcement powers, penalties, and private rights of action. It would expand the Attorney General’s authority to investigate and prosecute anticompetitive conduct, authorize civil and criminal penalties, require agency cooperation, and impose advance notice requirements for certain health care mergers, acquisitions, and contracting affiliations. It would also allow indirect purchaser recovery and class actions under state antitrust law, affecting businesses, health care entities, insurers, and provider organizations operating in Pennsylvania.
No committee transcripts or vote history were provided, so there is no recorded legislative sentiment to assess. From the bill text, the measure reflects a pro-enforcement, pro-competition policy approach, especially in health care markets, but the supplied record does not show whether lawmakers or stakeholders supported or opposed it.
The main likely points of contention are the bill’s broad expansion of antitrust liability and enforcement, including indirect purchaser suits, treble damages, criminal penalties, and Attorney General investigatory powers. Health care providers, facility systems, private equity-backed entities, insurers, and contracting affiliations may object to the 120-day premerger notice requirement and the additional reporting burden for transactions that may not be federally reportable. Supporters would likely emphasize consumer protection, competition, and scrutiny of consolidation in health care markets, while opponents may argue the bill could chill legitimate business combinations and create uncertainty for transactions.